AtaiBeckley Inc.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company dedicated to transforming patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. The company's mission is rooted in addressing significant unmet needs within mental health, leveraging rigorous science to deliver meaningful results. Its corporate headquarters are located in New York, NY.

AtaiBeckley's pipeline is focused on novel investigational therapies, primarily psychedelic-based neuroplastogens and 5-HT2AR agonists, targeting various mental health conditions. Key product candidates include BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD) and alcohol use disorder, VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCl) for social anxiety disorder (SAD). These therapies are currently in Phase 2 or Phase 3 clinical development, with BPL-003 having received FDA Breakthrough Therapy designation.

Formed in November 2025 through the strategic combination of atai Life Sciences and Beckley Psytech Limited, AtaiBeckley has since redomiciled to the United States. Recent notable developments include positive Phase 2a data for EMP-01 in Social Anxiety Disorder, demonstrating clinically meaningful improvements without adjunctive psychotherapy. The company also successfully completed an End-of-Phase 2 meeting with the FDA for BPL-003, with Phase 3 initiation anticipated in Q2 2026. Led by CEO and Co-Founder Dr. Srinivas Rao and Chairman Christian Angermayer, AtaiBeckley projects a cash runway into early 2029.